Decibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss Study

Zinger Key Points
  • HC Wainwright Sees FDA visibility and potential partnership as next steps for DB-020
  • Data support continued development of DB-020 for the irreversible condition for which no treatments are available

Decibel Therapeutics Inc DBTX reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020 to protect against hearing loss in cancer patients receiving cisplatin chemotherapy. 

The interim analysis showed that 88% of patients experienced ototoxicity in their placebo-treated ear, and of these patients, 87% were partially or completely protected from ototoxicity in their DB-020-treated ears.

DB-020 was generally well tolerated, with no significant safety issues observed.

Related: Decibel Therapeutics Shares Encouraging Preclinical Data From Hearing Loss Gene Therapy Programs.

DB-020, administered before cisplatin, had no apparent effect on systemic cisplatin levels.

Ears treated with DB-020 lost approximately 8dB on average from baseline.

DB-020 reduced cisplatin-induced loss of speech audibility by 80%.

HC Wainwright writes that at least one additional clinical trial (possibly registrational) is expected to be required to bring DB-020 closer to approval, the analyst notes.

In addition, the company expects that a set of preclinical studies may be needed to explore different cisplatin regimens to design a larger study in patients. 

Based on its delineating efficacy profile DB-020 could target a population of 270,000 patients/year in the U.S., E.U., and Japan with a launch in 2026 and projected peak sales of $1.8 billion on a 25% penetration.

Price Action: DBTX shares are up 21.60% at $2.73 during the market session on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorBiotechNewsPenny StocksHealth CareAnalyst RatingsMoversTrading IdeasGeneralwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!